- Saudi Arabia to Double Total Refining Capacity by 2015
- IMF Chief Does Not See Double-Dip US Recession
- Joint Effort Needed to Unwind Stimulus: APEC Leaders
- Obama to Outline Strategy to Boost US Exports to Asia
- Friday May See 'Risk Trade' Stalling; Dollar in Focus
- Former Bankers Look to Buy Failing Banks: Report
- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Cities With the Most Home Price Reductions
- EXCERPTS and IMAGES: Warren Buffett & Bill Gates - Keeping America Great
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- French economy expands 0.3 pct in Q3
- Airbus military transporter cleared for testing
- Chesapeake crabbers not going for Va.'s buyout
- Chinese president pledges to boost domestic demand
- US commerce secretary: Trade pacts must wait
- UK's Balfour Beatty acquires SpawMaxwell of Texas
- China rejects $28B in steel, chemical projects
- Boeing says first 747-8 emerges from factory
- Family hurt in Texas pipeline explosion files suit
Text Size 
SAN DIEGO - Arena Pharmaceuticals Inc. on Tuesday posted a smaller third-quarter loss following completion of clinical testing of its obesity drug candidate lorcaserin.
Arena said it lost $34.8 million, or 38 cents per share, compared with a loss of $56.2 million, or 76 cents per share, in the same quarter last year.
Revenue rose to $2.6 million from $1.9 million.
Thomson Reuters said analysts expected a loss of 34 cents per share and $2.4 million in revenue.
Arena has reported results from two late stage clinical studies of lorcaserin in the last few months. The company said its next priority is filing for marketing approval with the Food and Drug Administration. During the third quarter, the company's research and development costs dropped to $22.1 million from $47.5 million.
The company had about 91 million shares on the market, on average, during the third quarter. That compares to 73.9 million in the third quarter of 2008.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- They may have wrecked their companies or saved our economy. Tell us what you think.
- Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
- A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- PepsiCo is ramping up its onsite health facilities for workers.
Data is a real-time snapshot *Data is delayed at least 15 minutes